Multiple myeloma is the second most common blood-based malignancy, affecting approximately 20,000 new patients each year. There is currently no cure, and the survival rate is generally up to five years, even with treatment. More effective treatment options for multiple myeloma are urgently needed. SRI’s cancer drug discovery team is developing next-generation agents that may extend the lives of patients and lead to a cure.
SRI researchers have developed an anti-angiogenic molecule, SR16388, which has demonstrated antitumor activity against multiple myeloma in preclinical models and shows promise as a new therapeutic. Initial studies have shown that the molecule potently inhibits angiogenesis in lung and prostate cancers. SR16388 also inhibits the growth of multiple myeloma cells and experimental tumors.
Bone marrow image courtesy of
CDC/Dr. Gordon D. McLaren
This agent is different from current therapies because it blocks the ability of cancer cells in bone marrow to survive and grow in the low-oxygen microenvironments typical of this malignancy. In part, the drug does this by inhibiting the development of new blood vessels that supply oxygen and nutrients to multiplying cancer cells. SR16388 is in late-stage preclinical development by SRI, which will prepare the agent for entry into human clinical trials.